An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines

Investigational New Drugs

Volumn 28, Issue 5, 2010, Pages 554-560

  Giannopoulou, Efstathia ^a   Dimitropoulos, Konstantinos ^a   Argyriou, Andreas A ^a   Koutras, Angelos K ^a   Dimitrakopoulos, Fotinos ^a   Kalofonos, Haralabos P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Apoptosis; Lapatinib; Malignant glioma; Migration; MMPs; Proliferation; Sunitinib

Indexed keywords

GELATINASE A; GELATINASE B; LAPATINIB; MATRIX METALLOPROTEINASE; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ENZYME RELEASE; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; CELL MOTION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; PATHOLOGY; SECRETION (PROCESS); TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; GLIOMA; HUMANS; INDOLES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PYRROLES; QUINAZOLINES;

EID: 77956047415     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9290-0     Document Type: Article

References (28)

1. AA Argyriou A Antonacopoulou G Iconomou HP Kalofonos 2009 Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies Crit Rev Oncol Hematol 69 3 199 210 10.1016/j.critrevonc.2008.05.005 18602834
2. AM Omuro S Faivre E Raymond 2007 Lessons learned in the development of targeted therapy for malignant gliomas Mol Cancer Ther 6 7 1909 1919 10.1158/1535-7163.MCT-07-0047 1:CAS:528:DC%2BD2sXnsVyqu7k%3D 17620423
3. A Polyzos 2008 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors J Steroid Biochem Mol Biol 108 3-5 261 266 10.1016/j.jsbmb.2007.09.004 1:CAS:528:DC%2BD1cXhsFyntbY%3D 17945482
4. VR Adams M Leggas 2007 Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors Clin Ther 29 7 1338 1353 10.1016/j.clinthera.2007.07.022 1:CAS:528:DC%2BD2sXhtVemurjM 17825686
5. TJ Abrams LJ Murray E Pesenti VW Holway T Colombo LB Lee JM Cherrington NK Pryer 2003 Preclinical evaluation of the tyrosine kinase inhibitor 5Ul1248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer Mol Cancer Ther 2 1011 1021 1:CAS:528:DC%2BD3sXosVCqsb8%3D 14578466
6. KC Cuneo L Geng A Fu D Orton DE Hallahan AB Chakravarthy 2008 SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation Int J Radiat Oncol Biol Phys 71 3 873 879 1:CAS:528: DC%2BD1cXmsFOisrs%3D 18514780
7. S de Boüard P Herlin JG Christensen E Lemoisson P Gauduchon E Raymond JS Guillamo 2007 Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma Neuro Oncol 9 4 412 423 10.1215/15228517- 2007-024 17622648
8. AJ Schueneman E Himmelfarb L Geng J Tan E Donnelly D Mendel G McMahon DE Hallahan 2003 SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models Cancer Res 63 14 4009 4016 1:CAS:528:DC%2BD3sXlsFOjurc%3D 12873999
9. I Chu K Blackwell S Chen J Slingerland 2005 The Dual ErbB1/ErbB2 Inhibitor, Lapatinib (LAPATINIB), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer Cancer Res 65 18 25 1:CAS:528:DC%2BD2MXhvFahtw%3D%3D 15665275
10. C Gregory YE Whang W McCall X Fei Y Liu LA Ponguta FS French EM Wilson H Shelton 2005 Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth Clin Cancer Res 11 1704 1712 10.1158/1078-0432.CCR-04-1158 1:CAS:528: DC%2BD2MXitVKrsr8%3D 15755991
11. JA Blansfield D Caragacianu HR Alexander III MA Tangrea SY Morita D Lorang P Schafer, et al. 2008 Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy Clin Cancer Res 14 1 270 280 10.1158/1078-0432.CCR-07-1562 1:CAS:528:DC%2BD1cXoslKg 18172279
12. E Giannopoulou E Papadimitriou 2003 Amifostine has antiangiogenic properties in vitro by changing the redox status of human endothelial cells Free Rad Res 37 11 1191 1199 10.1080/10715760310001612559 1:CAS:528: DC%2BD3sXoslelsL4%3D
13. SK Kuwada CL Scaife J Kuang X Li RF Wong SR Florell RJ Coffey PD Gray 2004 Effects of trastuzumab on epidermal growth factor receptor-dependent and-independent human colon cancer cells Int J Cancer 109 291 301 10.1002/ijc.11686 1:CAS:528:DC%2BD2cXhvVCks70%3D 14750183
14. E Giannopoulou A Antonacopoulou K Floratou A Papavassiliou H Kalofonos 2009 Dual targeting of EGFR and HER-2 in colon cancer cell lines Cancer Chemother Pharmacol 63 6 973 981 10.1007/s00280-008-0820-9 1:CAS:528: DC%2BD1MXjslOlurc%3D 18751705
15. JL Fischel P Formento G Milano 2005 Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors Br J Cancer 92 6 1063 1068 10.1038/sj.bjc.6602428 1:CAS:528:DC%2BD2MXisVyisbg%3D 15756277
16. S Sathornsumetee DA Reardon A Desjardins JA Quinn JJ Vredenburgh JN Rich 2007 Molecularly targeted therapy for malignant glioma Cancer 110 1 13 24 10.1002/cncr.22741 17520692
17. D Hanahan J Folkman 1996 Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 3 353 364 10.1016/S0092-8674(00) 80108-7 1:CAS:528:DyaK28XltVSks7s%3D 8756718
18. A Zetser Y Bashenko HQ Miao I Vlodavsky N Ilan 2003 Heparanase affects adhesive and tumorigenic potential of human glioma cells Cancer Res 63 22 7733 7741 1:CAS:528:DC%2BD3sXptFOlsbk%3D 14633698
19. B Gril D Palmieri JL Bronder JM Herring E Vega-Valle L Feigenbaum DJ Liewehr, et al. 2008 Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain J Natl Cancer Inst 100 15 1092 1103 10.1093/jnci/djn216 1:CAS:528:DC%2BD1cXpslWktrc%3D 18664652
20. W Xing M Hamaguchi 2007 Effects of SHIP-1 on MMP2 secretion and invasion of SR3Y1 cells J Genet Genomics 34 4 285 293 10.1016/S1673-8527(07)60030-7 1:CAS:528:DC%2BD2sXlsVChtr4%3D 17498626
21. B Westermark CH Heldin M Nistér 1995 Platelet-derived growth factor in human glioma Glia 15 3 257 263 10.1002/glia.440150307 1:STN:280:DyaK287lslGgsA%3D%3D 8586462
22. PS Mischel TF Cloughesy 2003 Targeted molecular therapy of GBM Brain Pathol 13 1 52 61 12580545
23. JM Stommel AC Kimmelman H Ying, et al. 2007 Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies Science 318 5848 287 290 10.1126/science.1142946 1:CAS:528:DC%2BD2sXhtFCjt7vP 17872411
24. RK Goudar Q Shi MD Hjelmeland ST Keir RE McLendon CJ Wikstrand ED Reese, et al. 2005 Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition Mol Cancer Ther 4 1 101 112 1:CAS:528:DC%2BD2MXksFyqsA%3D%3D 15657358
25. RJ Motzer BI Rini RM Bukowski, et al. 2006 Sunitinib in patients with metastatic renal cell carcinoma JAMA 295 2516 2524 10.1001/jama.295.21.2516 1:CAS:528:DC%2BD28XlsV2rtLk%3D 16757724
26. RJ Motzer TE Hutson P Tomczak, et al. 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D 17215529
27. AK Koutras D Krikelis N Alexandrou I Starakis HP Kalofonos 2007 Brain metastasis in renal cell cancer responding to sunitinib Anticancer Res 27 6C 4255 4257 1:CAS:528:DC%2BD1cXhtVOmu7o%3D 18214028
28. CE Geyer J Forster D Lindquist, et al. 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743 10.1056/NEJMoa064320 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D 17192538